The review article was published in the Journal of the American College of Cardiology in August 2023 and was co-authored by Dr. Kyle Nelson, Dr. Valentin Fuster, and Dr. Paul Ridker.

The review found that low-grade systemic inflammation, as determined by hsCRP, is a more powerful determinant of recurrent cardiovascular events, cardiovascular death, and all-cause mortality than low-density lipoprotein cholesterol (LDL-C).

The review also found that the recent randomized trials of the interleukin-1 inhibitor canakinumab and of the microtubule polymerization inhibitor low-dose colchicine provide evidence that inflammation inhibition safely lowers cardiovascular event rates among statin-treated patients with a magnitude of effect similar to if not greater than that of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, ezetimibe, and other adjunctive lipid-lowering agents.

The review concluded that low-dose colchicine (0.5 mg po qd) is an effective and safe therapy for the secondary prevention of CAD. It is particularly beneficial for patients with high hsCRP levels.

Reference Article: https://doi.org/10.1016/j.jacc.2023.05.055

LM CAD treatment needs sophisticated decision-making. Recent clinical practice standards guide clinicians; however, treating individual individuals might be tough. Anatomy and physiology determine LM CAD manifestations. Recognizing the complexity of LM CAD, which rarely occurs alone and sometimes with multivessel disease, a treatment protocol using medical therapy alone or in combination with PCI or CABG is proposed. It is best to have a strategy for the heart team that takes into account clinical, procedural, operator, and institutional factors and uses collaborative decision-making to meet the needs and clinical situations of each patient.

Link to the original article: 

https://www.jacc.org/doi/full/10.1016/j.jacc.2022.09.034 

https://www.sciencedirect.com/science/article/pii/S0735109722070267?via%3Dihub

The understanding, diagnosis, and treatment options for transthyretin (TTR) amyloid is rapidly evolving. American Heart Association published a statement titled "Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association". I have tried to present the key elements of this article. 

Link: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000792